Competing interests
AC - Advisory boards: Celgene-BMS, Clinigen, Gilead-Sciences, Ideogen, Janssen, Roche, SecuraBIO, Takeda. Honoraria for lectures: Astrazeneca, Celgene-BMS, Clinigen, Gilead-Sciences, Incyte, Janssen, Novartis, Roche, Takeda. AP: Honoraria from BRISTOL-Myers Squibb, F. Hoffmann-LaRoche, Helssin Healthcare, Janssen, Celgene, Gilead Sciences, Incyte, Servier, Merck Sharp & Dohme and Takeda; VRZ - Honoraria from: Takeda, Janssen, Roche. GM - Janssen Honoraria, Consultant, Incyte: Honoraria, Consultant, Roche Honoraria, Consultant, Abbvie Honoraria, Consultant. LA - Consulting or Advisory Role: Gilead Sciences, Verastem, Eusa Pharma, Incyte and ADC Therapeutics Speakers’ Bureau: EUSA Pharma, Novartis Research Funding: Gilead Sciences Travel, Accommodations, Expenses: Roche, Celgene, Janssen-Cilag, EUSA Pharma. FC – Honoraria from; Roche, Servier, Gilead. SAP - Takeda (advisory board), Kyowa Kirin (advisory board), Roche (speaker). PC - Advisory boards: AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda. Honoraria for lectures: AbbVie, Amgen, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Sanofi, Takeda. The other authors declare that they have no conflict of interest.